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Abstract 
Objectives: Recently, phase III trials assessed a new combination of Lenalidomide, 
Bortezomib and Dexamethasone (RVD) in induction therapy in transplantation-eligible 
Multiple Myeloma (MM) patients, before consolidation with RVD and Lenalidomide 
maintenance. We present a retrospective study evaluating this approach with patients from the 
real life.  
Methods: We conducted a retrospective single-arm study to assess efficacy and safety of RVD 
combination in induction therapy before high-dose chemotherapy with Melphalan followed 
by autologous stem cell transplantation, and RVD consolidation followed by Lenalidomide 
maintenance, from February 2011 to May 2016.  
Results: Forty patients were enrolled. The mean age at diagnosis was 56 years. Median 
progression-free survival was 45 months and median overall survival was 76 months. The 
only factor found associated with better PFS was a negative minimal residual disease (p < 
0.01). Twenty-six (65%) patients experimented adverse events: 8 patients (20%) underwent 
12 serious AE (≥ grade 3). Treatment discontinuation occurred in 2 patients (5%) because of 
severe AE.  
Conclusion: To our knowledge, this work provides the first evidence of the efficacy and the 
safety of RVD combination in patients treated in common practice. 
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Introduction 
Over the last 15 years, quality and duration of life for patients suffering from Multiple 
Myeloma (MM) have greatly improved thanks to the emergence of new therapeutic classes as 
the immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide) and the proteasome 
inhibitors (bortezomib, carfilzomib, ixazomib) (1-9). High-dose chemotherapy following by 
autologous stem cell transplantation (ASCT) is recommended for all eligible MM patients. 
ASCT allows a better progression-free survival (PFS) and overall survival (OS) (10-14). 
High-dose melphalan (HDM) is mainly used as a conditioning regimen before ASCT (15-17). 
Recently, a combination of lenalidomide, bortezomib and dexamethasone (RVD) has been 
evaluated in induction, consolidation and maintenance therapy, in association or not with 
ASCT, showing a durable PFS and OS with this regimen (18,19) and a longer PFS when 
RVD therapy is combined with ASCT (20). Moreover, a lower risk of drug-related serious 
neuropathy has been reported with the association of lenalidomide with bortezomib compared 
to the association of thalidomide and bortezomib (21-23). Nevertheless, this regimen has 
never been reported in real life practice. So, we led a retrospective study evaluating a 
transplantation-based approach with RVD combination as induction and consolidation and 
lenalidomide maintenance outside clinical trials, with patients from the real life. 
  
Material and Methods 
We conducted a single-arm, retrospective study to assess efficacy and safety of RVD 
combination in transplantation-eligible patients. All the consecutive patients who received, in 
front-line, induction therapy with three (or four) 21-day cycles of RVD, which consisted of 
bortezomib (1.3 mg per square meter of body-surface area, administered subcutaneously on 
days 1, 4, 8, and 11), lenalidomide (25 mg, administered orally on days 1 through 14), and 
dexamethasone (40 mg, administered orally on days 1, 4, 8 and 11) for MM (diagnosed on 
IMWG criteria) before intensification with HDM (200 mg per square meter of body-surface 
area) and ASCT, and 2 cycles of RVD in consolidation therapy followed by lenalidomide (10 
mg/d, 21 days per 28-day cycle) maintenance (duration was at the practitioners’ discretion), 
from February 2011 to May 2016, in a French tertiary care center, were included. Some 
patients could have received prior cycles of a combination of bortezomib and dexamethasone 
in case of renal insufficiency at diagnosis. Concomitantly, the patients received 
thromboprophylaxis with daily aspirin (100 mg) or low molecular weight heparin, 
prophylaxis against herpes zoster with valaciclovir (500 mg twice a day) and bisphosphonate 
therapy monthly during the first 12 months. Data were collected retrospectively consulting the 
medical and pharmaceutical files. The primary endpoint was PFS. Secondary endpoints 
included OS and safety. Treatment response and disease progression were assessed according 
to the International Uniform Response Criteria for Multiple Myeloma (24). Toxicity was 
graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 
The minimal residual disease (MRD) evaluation was available for a part of patients. MRD 
was assessed using a 9 colors multiparametric flow cytometric immunophenotyping, using 
monoclonal antibodies against CD138-PC7, CD38-APC, CD19-ECD, CD56-PC5.5, CD200-
AA700, CD27-PB, CD45-KO, CyIgKappa-FITC and CyIgLambda-PE, all purchased from 
Beckman Coulter (Villepinte, France) in agreement with consensus guideline (25). Briefly, 
bone marrow (BM) aspirate, collected in tubes containing EDTA (ethylenediaminetetra-acetic 
acid) were washed in phosphate-buffered saline (PBS) and suspended in a PBS, 1.0% bovin 
serum albumin buffer adjusted to a final white cell concentration of 1–2×106/mL.  Next, 100 
µL of washed BM aspirates were briefly vortexed before incubation with monoclonal 
antibodies at room temperature in the dark (membrane markers first, then intracytoplasmic 
markers with Perfix NC kit from Beckman Coulter). Acquisition of CD45 positive cells and 
subsequent analyses of markers were performed using a NAVIOS 3 lasers flow cytometer 
(Beckman Coulter, Miami, USA). Myeloma cells were identified according to their 
immunophenotype at diagnosis. Negative MRD interpretation was based upon a minimal 
record of 200.000 cellular events in order to reach a sensitivity level of 10
-4
 cells. The study 
was approved by the institutional review board of the Assistance Publique des Hôpitaux de 
Marseille and conducted in accordance with the Declaration of Helsinki. Quantitative 
variables were described using medians and range and categorical variables were described 
using numbers and percentages. Durations of follow-up, PFS and OS were estimated by 
means of the reverse Kaplan–Meier method, the PFS were compared between groups using 
stratified log rank tests. P-values <0.05 were considered significant. All analyses were 
performed with the XLStat 2018 software.  
  
Results 
Characteristics of the population 
Forty patients were enrolled in our analysis. Baseline demographic and disease characteristics 
are summarized in Table 1. Median age at diagnosis was 58 years (range: 32 - 68 years). 
There were 12 female (30%) and 28 male (70%) patients. A high-risk cytogenetic was defined 
as the presence of a chromosome 17p deletion or a t(4;14) translocation. A fluorescent in situ 
hybridization (FISH) analysis was present in 26 patients (65%): t(4;14) translocation was 
found in 4 patients (15.4%) and 17p deletion in 1 (3.8%). Six patients received 2 prior cycles 
of bortezomib-dexamethasone before RVD induction due to an initial renal insufficiency. 
Twenty-six and 14 patients received 3 and 4 cycles of RVD induction, respectively. Ten 
patients were not under lenalidomide maintenance, 21 patients received lenalidomide 
maintenance for 1 year and 9 patients had lenalidomide maintenance until progressive disease. 
Safety 
Table 2 summarized the reported adverse events (AE). Eight patients (20%) underwent 12 
serious AE (≥ grade 3): neutropenia (n = 5), cutaneous (n = 2), thrombopenia (n = 2), 
neuropathy (n = 2), asthenia (n = 1). One patient (2.5%) suffered from deep venous 
thrombosis. Peripheral sensorimotor neuropathy was reported in 21 (52.5%) patients: grade 3 
in 2 cases (5%), grade 2 in 11 patients (27.5%), grade 1 in 8 patients (20%). Grade 3 
infectious events consisted in recurrent respiratory tract infections in 2 patients (5%). 
Treatment discontinuation occurred in 2 patients (5%) because of severe AE. There was no 
treatment-related mortality.  
RVD efficacy 
After RVD induction and before ASCT, 30 patients (75%) were in complete response (CR) or 
in very good partial response (VGPR). After ASCT and before RVD consolidation, 38 
patients (95%) were in stringent CR (sCR), CR or VGPR. After RVD consolidation and 
before lenalidomide maintenance, 37 patients (92.5%) were in VGPR or better. After all 
treatment sequences, 9 of the patients (22.5%) achieved an MRD negativity (Table 3). The 
median follow-up from diagnosis was 47 months (range: 15 - 86 months). At data cutoff, 20 
patients (50%) did not experiment relapse, 9 patients were dead, and 1 patient was lost to 
follow-up. Median PFS was 45 months (range: 10 – 75 months) and median OS was 76 
months (range: 14 – 86 months, Figure 1). High-risk cytogenetics, as International Staging 
System (ISS) disease stage at baseline, did not decrease significantly the PFS (p = 0.542 and p 
= 0.848, respectively, Figure 2). The patients who were in VGPR or better, at any moment of 
the evaluation, did not have a PFS significantly higher than those who were in partial 
response (PR), in stable disease (SD) or in progressive disease (PD) (Figure 3). PFS was not 
significantly influenced by the presence of lenalidomide maintenance (Figure 4). PFS was 
significantly longer in patients who achieved negative MRD (p = 0.008, Figure 5). 
Strategy after relapse 
After the first relapse, 9 of 17 patients (53%) were treated with an association of 
pomalidomide and dexamethasone. The 8 other patients received daratumumab (n = 1), 
combination of bortezomib-doxorubicin-dexamethasone (n = 1), combination of bortezomib-
cyclophosphamide-dexamethasone (n = 2) and new cycles of RVD (n = 4). After the second 
relapse, 2 patients were treated with daratumumab, 3 received pomalidomide, 3 received 
bendamustine, 1 received combination of bortezomib-cyclophosphamide-dexamethasone and 
1 was treated again by lenalidomide.  
  
Discussion 
To our knowledge, our work presents the largest cohort in the literature evaluating efficacy 
and safety of RVD combination in front-line treatment of MM in transplantation-eligible 
patients, in real conditions of use, i.e. outside clinical trial. With a prolonged follow-up 
(median: 47 months), we found a long median PFS of 45 months, and a durable median OS of 
76 months. This regimen was well tolerated with 20% of grade 3, or more, AE, and only 2 
toxicity-related discontinuations of treatment. The results are consistent with those of the 
phase III trial of Attal et al (20), who obtained a median PFS of 50 months in the group 
treated with ASCT after RVD induction, which is more favorable compared to a thalidomide-
bortezomib-dexamethasone (TVD) regimen. In a meta-analysis evaluating TVD, Leiba et al 
(26) found a post-induction VGPR rate (or better) around 60%, compared to 75% in our 
study. Moreover, the median PFS is higher with the RVD combination (45 months in our 
work) than with TVD (range: 18.3 - 33.1 months) (27-30). These results are similar to those 
found by Rosiñol et al in their integrated analysis of randomized clinical trials evaluating 
RVD or TVD (31): responses were deeper with RVD than TVD (≥ VGPR rate after induction 
with VRD vs VTD was 66.3% vs 51.2%; p = 0.00281). Surprisingly, the usual risk factors of 
poor response, as cytogenetic abnormalities, VGPR or better response after induction, ISS 
disease stage, did not seem to influence the PFS. This could be due to the small size of our 
cohort. However, MRD negativity is statistically associated with a longer PFS (p<0.01). Even 
though these results can be due to the small size of our cohort, these findings confirm that the 
absence of MRD is an important treatment target in MM, particularly after ASCT (18,20,32–
34). Safety was correct, with predictable and generally manageable toxicities. The main non-
hematological AE of RVD was mild peripheral neuropathy in 47.5% of patients, and serious 
peripheral neuropathy (≥ grade 3) occurred in only 5% of patients. No serious neuropathy 
occurred during lenalidomide maintenance. Only one case of neuropathy and one severe 
neutropenia led to a lenalidomide discontinuation. Thus, neuropathy risk appeared to be 
significantly lower with lenalidomide than with thalidomide. The incidence of thalidomide-
related neuropathy (all grades) varies between 10 and 83% (21–23,35–37). With TVD 
combination, the risk of peripheral neuropathy ≥ grade 3 is about 10 to 31% (26–29,38), in 
comparison to our 5% rate with RVD combination. This rate of peripheral neuropathy ≥ grade 
3 related to RVD was similar to the rate found by Rosiñol et al comparing RVD and TVD 
(5% versus 15.4%) (31). In our cohort, only one thromboembolic event underwent, but in a 
patient who had discontinued his thromboprophylaxis, while no herpes zoster infection 
occurred. Surprisingly, we did not find secondary malignant event as in previous studies 
(18,20). This could be due to the small effective of our cohort. But this confirms the low risk 
of second malignancy. The safety data are consistent with those collected in other studies with 
RVD combination (18-20). Overall, we found lower grade 3 or 4 AE with RVD (22.5%) than 
reported with TVD (57% in a recent meta-analysis) (26). Furthermore, a recent study showed 
superiority of RVD versus RD in patients non-candidates to ASCT (39). These results 
confirm the efficacy and the safety of this regimen, even in older patients thanks to a good 
profile of tolerance. So, we could apply the RVD regimen in patients non-candidates to 
ASCT, too. Even though our study suffers from its small size, it confirms the previous results 
about this strategy of MM treatment in transplantation-eligible patients. Moreover, we have 
led this study on patients from the real life, comparatively to the patients from controlled-
study, which they usually are younger, with fewer comorbidities and a stronger follow-up to 
avoid compliance issues than in real conditions of practice.  
Conclusion 
This work provides the first evidence of the efficacy and the safety of RVD combination as 
induction and consolidation after ASCT in patients treated in common practice.
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Figure 5
Characteristics  
Age (median, [range]) 58 [32-68] 
Sex (n, %) 
   Male 
   Female 
 
28 (70) 
12 (30) 
Type of myeloma (n, %) 
   IgG 
   IgA 
Light chain kappa 
   Light chain lambda 
   Non-secretory 
 
19 (47.5) 
11 (27.5) 
9 (22.5)  
0 (0) 
1 (2.5) 
International Staging System disease stage (n, 
%) 
   I 
   II 
   III 
Unknown 
 
13 (32.5) 
11 (27.5) 
13 (32.5) 
3 (7.5) 
FISH analysis (n, %) 
   t(4;14) translocation 
17p deletion 
   Unknown 
 
4 (15.4) 
1 (3.8) 
14 (35) 
Bone marrow plasma cells, % (median, [range]) 30 [3-94] 
Creatinine, µmol/L (median, [range]) 78 [49-444] 
Table 1: Baseline characteristic of patients and disease 
  
Adverse Events (AE) Any grade  
(at any time) 
Grade 3 or higher 
(at any time) 
Grade 3 or higher 
(VDR Induction 
or Consolidation) 
Grade 3 or 
higher 
(Lenalidomide 
Maintenance)  
n = 30 
Any AE 26 (65%) 9 (22.5%) 3 (7.5%) 6 (20%) 
Hematological disorder 
Thrombopenia 
Anemia 
Neutropenia 
 
7 (17.5%) 
2 (5%) 
10 (25%) 
 
2 (5%) 
0 
5 (12.5%) 
 
0 
0 
4 (10%) 
 
2 (6.67%) 
0 
1 (3.33%) 
Peripheral neuropathy 21 (52.5%) 2 (5%) 2 (5%) 0 
Asthenia 1 (2.5%) 1 (2.5%) 0 1 (3.33%) 
Gastrointestinal disorders 
Stomatitis 
Anorexia 
Gingival hemorrhage 
Nausea 
Constipation 
8 (20%) 
2 (5%) 
1 (2.5%) 
1 (2.5%) 
2 (5%) 
2 (5%) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Cytolytic hepatitis 1 (2.5%) 0 0 0 
Thromboembolism 1 (2.5%) 0 0 0 
Infections 2 (5%) 0 0 0 
Cutaneous 5 (12.5%) 2 (5%) 0 2 (6.67%) 
Table 2: Treatment-related adverse events 
  
Response (n, %) After induction 
therapy 
After ASCT After consolidation 
therapy 
sCR 0 (0) 1 (2.5) 9 (22.5) 
CR 9 (22.5) 12 (30) 11 (27.5) 
VGPR 21 (52.5) 25 (62.5) 17 (42.5) 
PR 10 (25) 2 (5) 3 (7.5) 
Table 3: Response rate after different phases of treatment 
ASCT: autologous stem cell transplantation; sCR: stringent complete response; CR: complete 
response; VGPR: very good partial response; PR: partial response 
 
